The short version of As-needed dosing fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-31 and is reviewed periodically as new material appears.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
==== Plants ==== The reduction of silver ions into silver nanoparticles has also been achieved using geranium leaves. It has been found that adding geranium leaf extract to silver nitrate solutions causes their silver ions to be quickly reduced and that the nanoparticles produced are particularly stable. The silver nanoparticles produced in solution had a size range between 16 and 40 nm. In another study different plant leaf extracts were used to reduce silver ions. It was found that out of Camellia sinensis (green tea), pine, persimmon, ginko, magnolia, and platanus that the magnolia leaf extract was the best at creating silver nanoparticles. This method created particles with a disperse size range of 15 to 500 nm, but it was also found that the particle size could be controlled by varying the reaction temperature. The speed at which the ions were reduced by the magnolia leaf extract was comparable to those of using chemicals to reduce. The use of plants, microbes, and fungi in the production of silver nanoparticles is leading the way to more environmentally sound production of silver nanoparticles. A green method is available for synthesizing silver nanoparticles using Amaranthus gangeticus Linn leaf extract.
The Cabinet Office confirms that Paula Vennells has been formally stripped of her CBE for "bringing the honours system into disrepute". A body found in the River Thames is formally identified as that of Abdul Shakoor Ezedi. 24 February Police are called to Willy's Chocolate Experience in Glasgow after the event – which was advertised as an immersive and interactive family experience using AI generated images – turns out to be a largely empty warehouse with a few props and decorations; attendees label the event a "scam" and "farce". In the following week, photos and videos from the shambolic event go viral online, garnering international media attention. Conservative MP and a former Deputy Chairman Lee Anderson has the party whip suspended over his allegations that "Islamists" have "got control" of London Mayor Sadiq Khan. Another round of joint UK–US air strikes are carried out against Houthi rebels. 25 February – The Post Office has hired investigators, including some former police officers, to look at the work of its own investigation into the Horizon IT scandal. 27 February Prince William unexpectedly pulls out of attending a memorial service for King Constantine II of Greece citing personal matters. South Staffordshire Council issue an enforcement notice on the landowner of The Crooked House requiring them to rebuild the building to its former dimensions and style as a public house.
D-amino acid + H2O + acceptor ⇌ a 2-oxo acid + NH3 + reduced acceptor This reaction is distinct from the oxidation reaction catalysed by D-amino acid oxidase that uses oxygen as a second substrate, as the dehydrogenase can use many different compounds as electron acceptors, with the physiological substrate being coenzyme Q. D-amino acid dehydrogenase is an enzyme that catalyzes NADPH from NADP+ and D-glucose to produce D-amino acids and glucose dehydrogenase. Some but not limited to these amino acids are D-leucine, D-isoleucine, and D-valine, which are essential amino acids that humans cannot synthesize because they are not included in their diet. Moreover, D-amino acids catalyzes the formation of 2-oxo acids to produce D-amino acids in the presence of DCIP which is an electron acceptor. D-amino acids are used as components of pharmaceutical products, such as antibiotics, anticoagulants, and pesticides, because they have been shown to be not only more potent than their L enantiomers, but also more resistant to enzyme degradation. D-amino acid dehydrogenase enzymes have been synthesized via mutagenesis with an ability to produce straight, branched, cyclic aliphatic and aromatic D-amino acids. Solubilized D-amino acid dehydrogenase tends to increase its affinity for D-alanine, D-asparagine, and D-α-amino-n-butyrate. In E. coli K12 D-amino acid dehydrogenase is most active with D-alanine as its substrate, as this amino acid is the sole source of carbon, nitrogen, and energy. The enzyme works optimally at pH 8.9 and has a Michaelis constant for D-alanine equal to 30 mM.
== Treatment == There is no cure for HCP caused by the deficient activity of coproporphyrinogen oxidase. Treatment of the acute symptoms of HCP is the same as for other acute porphyrias. Intravenous hemin (as heme arginate or hematin) is the recommended therapy for acute attacks. Acute attacks can be severe enough to cause death if not treated quickly and correctly. Hospitalization is typically required for administration of hemin, and appropriate drug selection is key to avoid exacerbating symptoms with drugs that interact poorly with porphyrias. Proper drug selection is most difficult when it comes to treatment of the seizures that can accompany HCP, as most anti-seizure medications can make the symptoms worse. Gabapentin and levetiracetam are two anti-seizure drugs that are thought to be safe. In patients where management of symptoms is difficult even with hemin, liver transplant is an option before the symptoms have progressed to advanced paralysis. Combined liver and kidney transplants are sometimes undertaken in people with kidney failure. Long-term treatment of acute porphyrias is centered on the avoidance of acute attacks by eliminating precipitating factors, such as drugs, dietary changes, and infections. Females often have attacks coincident with their menstrual cycle, which can be managed effectively with hormonal birth control. Because of the reduced penetrance of HCP, family members of a patient may carry the same mutation without ever presenting with symptoms.
genomic imprinting An epigenetic phenomenon that causes genes to be expressed in a manner dependent upon the particular parent from which the gene was inherited. It occurs when epigenetic marks such as DNA or histone methylation are established or "imprinted" in the germ cells of a parent organism and subsequently maintained through cell divisions in the somatic cells of the organism's progeny; as a result, a gene in the progeny that was inherited from the father may be expressed differently than another copy of the same gene that was inherited from the mother.
Sources: en.wikipedia.org
Fox, Sidney W. (1957). Introduction to protein chemistry. New York: Wiley. Fox, Sidney W. (1965). The origins of prebiological systems and of their molecular matrices. New York: Acad. Pr. Fox, Sidney W.; Duane L Rohlfing, Aleksandr Ivanovich Oparin (1972). Molecular evolution: prebiological and biological. New York: Plenum Press. Fox, Sidney W., Klaus Dose; with a foreword by A. Oparin (1977). Molecular evolution and the origin of life (Rev. ed. ed.). New York: M. Dekker. Fox, Sidney W. (1984). Individuality and determinism: chemical and biological bases. New York: Plenum Press. Ho, edited by Mae-Wan; Fox, Sidney W. (1988). Evolutionary processes and metaphors. Chichester: Wiley. pp. 333. ISBN 0-471-91801-6. Fox, Sidney W. (1988). The emergence of life: Darwinian evolution from the inside. Basic Books.
Bryant Park is a 9.6-acre (3.9 ha), privately managed public park in the New York City borough of Manhattan. It is located between Fifth Avenue and Avenue of the Americas (Sixth Avenue) and between 40th and 42nd Streets in Midtown Manhattan. The eastern half of Bryant Park is occupied by the Main Branch of the New York Public Library. The western half contains a lawn, shaded walkways, and amenities such as a carousel, and is located entirely over an underground structure that houses the library's stacks. The park hosts several events, including a seasonal "Winter Village" with an ice rink and shops during the winter. The first park at the site was opened in 1847 and was called Reservoir Square due to its proximity to the Croton Distributing Reservoir. Reservoir Square contained the New York Crystal Palace, which hosted the Exhibition of the Industry of All Nations in 1853 and burned down in 1858. The square was renamed in 1884 for abolitionist and journalist William Cullen Bryant. The reservoir was demolished in 1900 and the New York Public Library's main branch was built on the site, opening in 1911. Bryant Park was rebuilt in 1933–1934 to a plan by Lusby Simpson. After a period of decline, it was restored in 1988–1992 by landscape architects Hanna/Olin Ltd. and architects Hardy Holzman Pfeiffer Associates, during which the park was rebuilt and the library's stacks were built underneath. Further improvements were made in the late 20th and early 21st centuries.
He has about 200 peer-reviewed papers including: highly-cited reviews that quantify MRI relaxation times ('T1' and 'T2') in normal and diseased tissues covering a broad range of low and higher field MRI systems; the 'Handbook of Magnetic Resonance Spectroscopy in vivo'; and the history of the development of localized NMR methods. He has over 50 patents, including high-field MRI (>0.7 Tesla), spin-echo MRI, 'crusher' gradients, 'fat-saturation', '3D-slab' MRI, 'point resolved spectroscopy' (PRESS), 2D spatially-selective pulses, and MRS imaging. He is a Fellow and 1989 Gold Medal recipient of the International Society of Magnetic Resonance in Medicine, 2012 Sir Peter Mansfield Lecturer; and recipient of General Electric Company's Gold Silver and Bronze patent medallions, its Dushman Award and its Coolidge Fellowship and medal. He was the 2015 Gold Medal recipient of the American Roentgen-Ray Society and the 2018-2019 Newton Abraham Visiting Professor at Oxford University U.K.
Soul music became the popular music of young adults, therefore, we changed with the times. Now since I played trumpet as a youth in high school, it was natural to play dual harmonies with Frank on many of these songs. This was due to the horn charts that were inherent in the music of that time period." With a change in style, came a change in venues, as The Sinners began expanding their base, performing at Italia East (where their second record was made), Bob's Inn in Brewerton, The Turn On, The Red Dog Saloon, Manlius, NY, and more S.U. (Syracuse University) frat parties. "We also played an O.C.C. (Onondaga Community College) commencement" According to Ron Lauback "I got up in line next to the chancellor of the college, and shook hands with the graduating students and wished them good luck." The Saint and the Sinners continued until summer 1968, when Tommy Forrest left to re-join The Monterays (Frank Sgroi would resurface with The Seven). After The Saint and the Sinners folded Ron and George Day briefly worked with The Monterays before forming Airborne (1969). This group featured a female lead singer (Karen Franklin) and was even more soul based, but Ron inexplicably left music a year later to devote more time to his family and career. Airborne did record a number of demos that were remastered and given limited release on the 3 Records label in 2000.
Merck Foundation - founded in 1957, the foundation has donated over $1 billion to charitable causes to promote health equity. In 2012, the foundation ended its donations to the Boy Scouts of America citing its discrimination against gay people. Patient assistance programs to offer access to pharmaceuticals to those unable to afford its medications. Provides funding to Hilleman Laboratories, an India-based non-profit research organization dedicated to the development of low-cost vaccines for use in developing countries. Merck for Mothers prevents maternal mortality. Merck produces Mectizan (ivermectin), an anti-parasitic medicine traditionally used to treat onchocerciasis, solely for donation to people in Africa, Latin America, and Yemen. The donation program has significantly reduced the incidence of the disease.
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.